Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Atezolizumab
Bevacizumab
Cancer immunotherapy
Metastatic
Renal cell carcinoma
Second line
Sunitinib
Vascular endothelial growth factor inhibitor
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
16
04
2020
accepted:
05
01
2021
pubmed:
9
3
2021
medline:
10
2
2022
entrez:
8
3
2021
Statut:
ppublish
Résumé
The use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively. To evaluate the efficacy and safety of atezolizumab + bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with mRCC. IMmotion150 was a multicenter, randomized, open-label, phase 2 study of patients with untreated mRCC. Patients randomized to the atezolizumab or sunitinib arm who had investigator-assessed progression as per RECIST 1.1 could be treated with second-line atezolizumab + bevacizumab. Patients received atezolizumab 1200 mg intravenously (IV) plus bevacizumab 15 mg/kg IV every 3 wk following disease progression on either atezolizumab or sunitinib monotherapy. The secondary endpoints analyzed during the second-line part of IMmotion150 included objective response rate (ORR), progression-free survival (PFS), and safety. PFS was examined using Kaplan-Meier methods. Fifty-nine patients in the atezolizumab arm and 78 in the sunitinib arm were eligible, and 103 initiated second-line atezolizumab + bevacizumab (atezolizumab arm, n = 44; sunitinib arm, n = 59). ORR (95% confidence interval [CI]) was 27% (19-37%). The median PFS (95% CI) from the start of second line was 8.7 (5.6-13.7) mo. The median event follow-up duration was 19.4 (12.9-21.9) mo among the 25 patients without a PFS event. Eighty-six (83%) patients had treatment-related adverse events; 31 of 103 (30%) had grade 3/4 events. Limitations were the small sample size and selection for progressors. The atezolizumab + bevacizumab combination had activity and was tolerable in patients with progression on atezolizumab or sunitinib. Further studies are needed to investigate sequencing strategies in mRCC. Patients with advanced kidney cancer whose disease had worsened during treatment with atezolizumab or sunitinib began second-line treatment with atezolizumab + bevacizumab. Tumors shrank in more than one-quarter of patients treated with this combination, and side effects were manageable.
Sections du résumé
BACKGROUND
The use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively.
OBJECTIVE
To evaluate the efficacy and safety of atezolizumab + bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with mRCC.
DESIGN, SETTING, AND PARTICIPANTS
IMmotion150 was a multicenter, randomized, open-label, phase 2 study of patients with untreated mRCC. Patients randomized to the atezolizumab or sunitinib arm who had investigator-assessed progression as per RECIST 1.1 could be treated with second-line atezolizumab + bevacizumab.
INTERVENTION
Patients received atezolizumab 1200 mg intravenously (IV) plus bevacizumab 15 mg/kg IV every 3 wk following disease progression on either atezolizumab or sunitinib monotherapy.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
The secondary endpoints analyzed during the second-line part of IMmotion150 included objective response rate (ORR), progression-free survival (PFS), and safety. PFS was examined using Kaplan-Meier methods.
RESULTS AND LIMITATIONS
Fifty-nine patients in the atezolizumab arm and 78 in the sunitinib arm were eligible, and 103 initiated second-line atezolizumab + bevacizumab (atezolizumab arm, n = 44; sunitinib arm, n = 59). ORR (95% confidence interval [CI]) was 27% (19-37%). The median PFS (95% CI) from the start of second line was 8.7 (5.6-13.7) mo. The median event follow-up duration was 19.4 (12.9-21.9) mo among the 25 patients without a PFS event. Eighty-six (83%) patients had treatment-related adverse events; 31 of 103 (30%) had grade 3/4 events. Limitations were the small sample size and selection for progressors.
CONCLUSIONS
The atezolizumab + bevacizumab combination had activity and was tolerable in patients with progression on atezolizumab or sunitinib. Further studies are needed to investigate sequencing strategies in mRCC.
PATIENT SUMMARY
Patients with advanced kidney cancer whose disease had worsened during treatment with atezolizumab or sunitinib began second-line treatment with atezolizumab + bevacizumab. Tumors shrank in more than one-quarter of patients treated with this combination, and side effects were manageable.
Identifiants
pubmed: 33678522
pii: S0302-2838(21)00003-8
doi: 10.1016/j.eururo.2021.01.003
pmc: PMC9357270
mid: NIHMS1819594
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Vascular Endothelial Growth Factor A
0
Bevacizumab
2S9ZZM9Q9V
atezolizumab
52CMI0WC3Y
Sunitinib
V99T50803M
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
665-673Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014599
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA101942
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Lancet Oncol. 2017 Aug;18(8):982-983
pubmed: 28759367
Clin Genitourin Cancer. 2013 Mar;11(1):45-50
pubmed: 23041453
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124
pubmed: 29229461
Cancer Res. 2013 May 15;73(10):2943-8
pubmed: 23440426
Clin Genitourin Cancer. 2016 Feb;14(1):56-62
pubmed: 26404107
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Clin Cancer Res. 2012 Dec 15;18(24):6580-7
pubmed: 23087408
J Clin Oncol. 2016 Mar 10;34(8):833-42
pubmed: 26755520
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
J Immunother Cancer. 2019 Dec 20;7(1):354
pubmed: 31856918
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Clin Genitourin Cancer. 2013 Sep;11(3):283-289.e1
pubmed: 23684421
J Natl Compr Canc Netw. 2009 Jun;7(6):618-30
pubmed: 19555584
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059